IL-23 Inhibitors in Dermatology - Drug, Mechanism of Action, Use, Side-effects

Поділитися
Вставка
  • Опубліковано 18 лис 2024

КОМЕНТАРІ • 6

  • @JahnaviChaduvula
    @JahnaviChaduvula Рік тому

    Thankyou very much sir😊

  • @athomas3386
    @athomas3386 9 місяців тому

    Very Informative Thank you
    Do you think that the lower Pasi75 score and not showing a Pasi90 score of Risankizumab is due to the fact that at week 16 only two doses have been administered.
    As opposed to say Guselkumab which at week 16 is 2 weeks past the third dose accounting for its higher Pasi result ?

    • @sabhderma
      @sabhderma  9 місяців тому

      That is a very good query ☺️ frankly, I don't know. But I can incur that not all biologics are similar, or have similar pharmacokinetics. Thus, every biologic has its own dosage schedule. That is why, any new biologic is compared to an older established one on the basis of efficacy. I doubt that evaluation at a fixed point of time has anything to do with the number of dosages, but is rather related to their speed or efficacy. So we may say that risankizumab may be slow acting as compared to guselkumab. That is one of the inferences that I can gather. Hope this helps 😊

  • @reshmaramani7732
    @reshmaramani7732 Рік тому

    Thank you sir😊